Surrozen is discovering and developing novel regenerative
medicines with a focus on unlocking the self-renewal properties of
the body through specific modulation of the Wnt signaling
The Wnt pathway plays a critical role in stem cell maintenance,
tissue regeneration and other important developmental processes.
Surrozen is implementing a platform of surrogate Wnt signaling
molecules to selectively activate the Wnt pathway for the treatment
of injury and disease - overcoming key hurdles that have held back
drug development efforts in this promising area of biology.
Our technologies are targeted bi-specific antibodies that mimic
the activity of Wnt or R-spondin ligands in modulating Wnt
signaling pathways for selective tissue regeneration. We have
established a robust antibody discovery effort comprising protein
engineering, cell biology and in vivo pharmacology. We have
discovered antibody-based agonists that can selectively stimulate
Wnt signaling, resulting in tissue specific cell proliferation, and
have established in vivo proof of concept for our proprietary
molecules in animal models of osteoporosis, liver cirrhosis,
inflammatory bowel disease and acute kidney injury.
Surrozen was founded by five leading-edge scientists: K.
Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D.,
Ph.D. from Stanford University; Claudia Janda, Ph.D. from the
Princess Maxima Center for Pediatric Oncology; and Hans Clevers,
M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center.
Each has conducted extensive research on Wnt signaling, with
findings that together shape Surrozen's technology and approach to
The Director of Biology will report to the Vice President,
Biology and will be a highly motivated biology expert who will
participate in and drive the advancement of novel therapeutics for
the tissue regeneration and treatment of liver diseases,
inflammatory bowel disease, retinal diseases, etc. This life
sciences research leader will be immersed in the development and
implementation of early and late stage research programs while
investigating the mechanism of action of candidate lead molecules
and clinical development compounds and will help in identifying new
targets to ensure that a robust pipeline of product candidates is
moving towards the clinic. This person will work closely with the
members of the executive team and provide both strategic and
day-to-day guidance to the scientific team.
Essential Duties and Responsibilities
Primary responsibilities will be to lead the scientific team to
understand the mechanism of action of candidate lead molecules and
clinical development compounds and support drug discovery. The
successful candidate will be expected to independently design,
execute and manage internal research projects, collaborate with
other functional groups within the broader organization and manage
external collaborations. In addition, the candidate will contribute
to patent filings and publications and present research finding to
various audiences including senior management